PFEPfizer

$28.27+23% 1Y

$28.27

$22.4452 weeks$29.03

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 without data

What the price assumes~+0% a yearderived · Jun 28, 2026

Priced for a decline (~0% a year). Little growth is priced in even as revenue fell 7% a year over three years, potential value, or a value trap.

Vs its own P/E rangedearest in 39 quartersderived

Expensive vs its own history: P/E 37.2 vs a 13.7 median over 39 quarters (+172% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 78% of the market

FCF yieldbetter than 74% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Pfizer trades at 37.2× earnings against 26.2× for the median Drug Manufacturers - General name, more expensive than its own group.

37.2

Trailing P/E · Drug Manufacturers - General median 26.2 · 1.42× the median: the market pays up for this one

Price / sales: 2.26
Price / sales · today's price, trailing year to Jun 28, 2026
Free cash flow yield: 7.6%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: 0.00%
Growth the price implies · The price pays for 0.00% free cash flow growth a year for a decade; the business has delivered +0.99% a year over the last three.